Solas Capital Management, LLC 13D and 13G filings for Fennec Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-14 10:38 am Sale | 2026-06-30 | 13G | FENNEC PHARMACEUTICALS, INC. O FENC | Solas Capital Management, LLC | 1,889,366 5.400% | -592,832 (-23.88%) | Filing |
| 2026-05-15 10:58 am Purchase | 2026-03-31 | 13G | FENNEC PHARMACEUTICALS, INC. O FENC | Solas Capital Management, LLC | 2,482,198 7.200% | 231,279 (+10.27%) | Filing |
| 2025-02-14 1:00 pm Purchase | 2024-12-31 | 13G | FENNEC PHARMACEUTICALS, INC. O FENC | Solas Capital Management, LLC | 2,250,919 8.200% | 327,383 (+17.02%) | Filing |
| 2024-11-14 1:58 pm Purchase | 2024-09-30 | 13G | FENNEC PHARMACEUTICALS, INC. O FENC | Solas Capital Management, LLC | 1,923,536 7.000% | 545,023 (+39.54%) | Filing |
| 2024-02-14 10:47 am Purchase | 2023-12-31 | 13G | FENNEC PHARMACEUTICALS, INC. O FENC | Solas Capital Management, LLC | 1,378,513 5.200% | 1,378,513 (New Position) | Filing |